top of page

CSTI-100 / HBS-102

MCHR1 antagonist for the treatment of rare neurological disorders.

CSTI-100 / HBS-102

In 2021 ConSynance reached an asset purchase agreement with Harmony Biosciences (HMBY) for an early clinical asset, CSTI-100, now renamed HBS-102. Harmony is currently evaluating the potential of HBS-102, a first-in-class MCHR1 antagonist, in a variety of rare neurological areas.

Harmony Biosciences holds the full development and commercialization rights globally, with the exception of Greater China. ConSynance holds the development and commercialization rights in Greater China.

For further information please refer to Harmony’s website:

three features_edited.jpg

bottom of page